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ABSTRACT
Langerhans cell histiocytosis is a rare disease. Depending
on which organs are involved, the disease may prove
rapidly fatal, develop a chronic reactivating but therapy-
responsive pattern or resolve spontaneously.
Understanding of the pathology of the disease is
progressing rapidly, and while clinical trials of standard
chemotherapy agents continue, it is likely that novel
targeted therapy will become feasible in the next decade.
Permanent consequences of the disease are more
commoner than generally realised.
Langerhans cell histiocytosis (LCH) is characterised
by aberrant proliferation of a cell type normally
found as an epidermal histiocyte—the Langerhans
cell (LC). This cell was first recognised by Paul
Langerhans in 1868, when, owing to its dendritic
processes, he described it as a neuronal cell but
subsequently realised this was not the case.1 It was
not until much later, after the concept of the
histiocyte as a tissue macrophage had emerged
during the 1940s, that the immune function of the
LC in antigen presentation was appreciated.2 In
1953, having identified abnormal histiocytes in
three related syndromes, eosiniphilic granuloma of
bone, Letterer–Siwe disease and Schu¨ller–Christian
disease, Lichtenstein grouped them together as
‘‘Histiocytosis X (HX)—related manifestations of a
single nosologic entity.’’3 Over the ensuing decade,
Basset and Nezelof investigated novel intracellular
granules in histiocytes in HX lung and bone lesions
which were subsequently recognised as similar to
those described in normal skin LC by Birbeck’s
team.4 Collaboration between these groups
revealed that the ‘‘Birbeck’’ granules found in
normal LC and histiocytes from skin, lung and
bone in HX lesions were identical, leading to the
gradual acceptance of the term LCH to replace
HX.4–6 The intriguing questions of what function
Birbeck granules have and why a cell normally
found in the epidermis should be involved in a
disease with such diverse manifestations as LCH
remain largely unanswered. Interestingly, how-
ever, recent reports from murine studies have
described the finding of LC-like dendritic cell
subsets in most non-lymphoid tissues.7 Further
studies may provide similar insights into the
behaviour of human LCH cells.
Tissues characteristically involved in LCH are
bone, skin, lung, liver, spleen, bone marrow, lymph
nodes and the hypothalamic–pituitary region,
although involvement of other organs such as the
bowel can occur. Depending on organ involve-
ment, staging distinguishes between single system
(SS) and multisystem (MS) disease. In the context
of MS disease, involvement of certain tissues—
bone marrow, liver, spleen and lungs—so-called
risk organ positivity (MSRO+), is associated with a
worse prognosis.8 In cases of SS, bony or nodal
disease several sites can be involved, which is then
described as multifocal (MF) disease.
AETIOLOGY AND EPIDEMIOLOGY
Despite reports of clonality of LCH cells, there is
still debate about whether the disease is malignant
or reactive as the natural history ranges from
rapidly progressive, fatal, multiorgan failure,
through chronic reactivating disease to sponta-
neous remission.9 10 It remains unclear whether the
primary disorder is within the LCH cells or, given
that they are found among a background of other
activated immune cells, they are victims of a
‘‘cytokine storm.’’11
There are reports of LCH occurring in associa-
tion with other malignancies. The Malignancy
Registry of the International Histiocyte Society has
identified in excess of 150 cases.12 In some cases of
LCH occurring in children previously treated for T
cell acute lymphocytic leukaemia the cells share
genetic rearrangements with the original leukaemic
clone.13 In other cases, disease develops after LCH
has been treated, suggesting the possibility of
therapy-induced second malignancy, such as acute
myeloid leukaemia (AML) occurring after treat-
ment with etoposide.14
LCH is a rare disease. A recent population-based
French study has given an estimated annual
incidence of 4.6 per million children (age 0–
14 years).15 Similarly, a British Paediatric
Surveillance Unit (BPSU) study in conjunction
with Newcastle University (NU) during 2003/5
revealed 94 cases, giving an annual incidence of
four per million UK & Republic of Ireland children
(age 0–15 years).16 In this study, single system
bony disease accounted for 63 cases, of which 10
had MF involvement. Of the 18 cases of MS disease
without risk organ involvement (MSRO2), 14 had
bony disease compared with eight with skin
involvement. By contrast, all of the seven with
MSRO+ disease had skin involvement, but only one
had bony disease. The median age at diagnosis in
the MSRO+ group was 0.7 years compared with
3.2 years in the MSRO2 children and 6.7 years in
the SS cases. There were three deaths reported, all
in MSRO+ cases.
Twin studies and familial clustering suggest the
possibility that a genetic predisposition may exist
in some cases, but there is nothing to suggest that a
single candidate gene may be involved.17 There is
no convincing evidence implicating specific envir-
onmental factors or infectious agents, although
several studies have looked at the role of viruses in
the aetiology of LCH. Cigarettes have been
implicated in a particular form of lung LCH seen
predominantly in young adults who smoke.18
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PRESENTATION
The time interval between onset of symptoms and diagnosis is
very variable. In the BPSU/NU study, intervals ranged from a
few days to over 3 years for a patient with a single bony lesion
(median 10 weeks).16 The shortest time was for patients with
MSRO+ disease (median 9, range 3.1 to 26.7 weeks).
The commonest form of LCH is SS unifocal bony disease,
previously known as eosinophilic granuloma. The skull vault is
a common site in younger children where it presents as a
painless lump. On examination, the lesion is fluctuant, and the
rim of the bony defect in the skull may be palpable. Lesions of
the orbit may present with proptosis and the mastoid with
swelling and chronic aural discharge. Disease may involve the
mandible, giving rise to ‘‘floating’’ teeth. Vertebral, pelvic and
long bone lesions may present with musculoskeletal pain.
Rarely, a child may present with cervical pain or torticollis as a
result of a lesion in the odontoid peg. Although this is an
unusual site, we have included an illustration (fig 1) to
emphasise the potential for disaster in this circumstance. The
disease may rarely involve the bones of the hands and feet.
Some 15% of children with SS bony disease may be found to
have more than one site of involvement at the time of initial
diagnosis.16
Cutaneous LCH typically presents as a widespread eczema-
tous rash. In neonates, the lesions may present as vesicles with a
weal and flare-like appearance (fig 2), which might not be
recognised as LCH, as it is not the characteristic appearance
reported in the literature. Umbilicated papules mimicking
molluscum contagiosum and characteristic nail changes may
be seen.19 Skin disease varies from 3% of SS presentations in the
UK and Ireland16 to 10% in Sweden20 and 23% in France.15 A
spontaneously regressing form can occur congenitally—so-
called Hashimoto–Pritzker self-healing reticulohistiocytosis.21
It is important to carefully follow infants with presumed
isolated skin disease, as some may progress to multisystem
involvement with time. Other SS presentations include localised
lymphadenopathy and diabetes insipidus (DI) due to posterior
pituitary involvement.
The majority of MSRO2 cases present with bony involvement.
Less than half have skin disease, and posterior pituitary, lymph
node and other rare site involvement make up the rest.16 MSRO+
disease most commonly presents in infancy with an extensive
skin rash and failure to thrive. Skin involvement predominates
in MS disease under the age of 1 year, reflecting its strong
association with risk organ involvement in this age group.15 Up
to half the cases may have bony disease. Specific risk organ
involvement may result in cytopenias, liver dysfunction,
hepatosplenomegaly and lung infiltration.
LCH in adults
Adults can develop the same manifestations of LCH as children.
The problem is that they tend to be seen in multiple clinics by
subspecialty teams concentrating on whichever system is
causing their predominant clinical problem. Efforts are ongoing
to increase the awareness of the need for a multidisciplinary
approach, including opening adult protocols and holding adult-
orientated clinical meetings.22 23 There is a form of isolated
pulmonary involvement that occurs almost exclusively in young
adults, in particular smokers. It is not clear at this time what
treatment should be used to salvage cases, where, despite
smoking cessation, the disease progresses to end-stage lung
failure requiring transplantation.24
DIAGNOSIS AND STAGING
A detailed history is important to ascertain past or current
symptoms indicating involvement of a particular organ system.
Areas on which to focus include odd rashes, atypical muscu-
loskeletal pain, aural discharge and excessive thirst.
Investigations are organ-system-based with the intention of
establishing disease extent and obtaining diagnostic biopsy
material. The diagnosis of LCH is confirmed by the character-
istic morphology and the presence of CD1a or CD207 (Langerin)
positive histiocytic cells. Nowadays, electron-microscopic con-
firmation of the presence of Birbeck granules is rarely used.
Depending on the degree of involvement of each system, a
prognostic score has been devised, which may subsequently be
used to monitor response and modify therapy.25
Bone
Plain x ray of the majority of bone lesions will demonstrate the
characteristic punched out, radiolucent appearance. However,
lesions in the skull base may not be obvious, and vertebral
involvement may appear as a crush fracture. Rarely bone lesions
may present with a more atypical ‘‘tumour-like’’ appearance.
Having found a lesion, CT or MR imaging may help ascertain
the extent and character of the lesion prior to biopsy. If the
lesion is in a site which is difficult to biopsy, further screening x
rays may be performed to find a more amenable site. Once the
diagnosis is established, the rest of the skeleton should be
imaged for other lesions. This is traditionally done by
performing an age-appropriate skeletal survey rather than a less
sensitive isotope bone scan.26 Recently, whole-body PET CT and
MRI have been proposed as more sensitive modalities.27 28
Skin
The extent of skin involvement should be documented, and the
mouth and perineum carefully inspected. The axillae, groins and
skin creases may be severely affected, and ulcerated lesions may
occur. A punch biopsy should be obtained from an area of
clearly active disease.
Lymph nodes
Lymph nodes draining involved bone or skin may be affected,
but occasionally LCH may occur in isolated nodes. This usually
comes to light after a suspicious node has been biopsied to
exclude a diagnosis of malignancy. In the context of MS disease,
it is not necessary to confirm nodal involvement, unless there
are no other areas suitable for biopsy.Figure 1 CT reconstruction of lytic lesion eroding odontoid peg.
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Hypothalamic–pituitary region
In the absence of symptoms, a normally concentrated early
morning urine is adequate to exclude DI in a child with LCH;
otherwise a formal water deprivation test is necessary.
Occasionally, a child presents with isolated DI, and LCH is
included in the differential diagnosis. If screening tests for other
manifestations of LCH and germ-cell tumour markers are
negative, it may be necessary to make a presumptive diagnosis
of LCH rather than attempt a pituitary biopsy. In these
circumstances, MRI features compatible with pituitary LCH
should be seen (absence of the posterior bright spot and
thickening of the stalk) and regular follow-up examinations
performed to confirm a non-progressive lesion. Rarely, LCH
may present as a hypothalamic or other intracranial mass,
which should normally be confirmed by stereotactic biopsy.
Gastrointestinal tract
While bowel disturbances are common in children with wide-
spread LCH, pathological histiocytic infiltration of bowel is
rare.29 Involvement should only be diagnosed on the basis of
positive endoscopic biopsies.
Bone marrow
Cytopenias suggesting bone marrow involvement in LCH are an
ominous finding associated with a poor prognosis but are not
necessarily always due to direct marrow infiltration by LCH.30
CD1a positive cells may be found in relatively low numbers in
bone marrow, and it is possible that any cytopenia may be due to
concurrent macrophage activation or secondary haemophagocy-
tosis.31 Consequently, for staging purposes, haematopoietic
involvement is defined according to specified levels of cytopenia.32
Lungs
As it is often asymptomatic, lung involvement should be
considered in all cases of MS disease. Pulmonary function tests
may be abnormal, and interstitial infiltrates may be visible on
plain x ray in the early stages. With progression, reticulonodular
changes appear followed by cyst formation giving the classical
honeycomb lung appearance. If there are any suspicious
changes, these should be investigated further with high-
resolution CT. Bronchoalveolar lavage might not provide
diagnostic material unless accompanied by transbronchial
biopsy but may be useful in excluding opportunistic infection
in severely ill patients.33 Lung biopsy is indicated when the
presence or absence of pulmonary involvement will influence
treatment, for example in the rare situation where lung is the
only potential risk organ. Even in such cases, it is not entirely
clear that lung involvement without another risk organ involved
has a poor prognosis.34 35 All patients with suspected or proven
LCH should have a chest x ray prior to general anaesthesia to
exclude any cystic changes which may predispose to pneu-
mothorax occurring during assisted ventilation.36
Liver and spleen
For staging purposes, involvement is diagnosed in the presence
of hepatosplenomegaly or abnormal liver function tests.32 In
some cases, ultrasound, cholangiography and liver biopsy may
be indicated to distinguish between sclerosing cholangitis due to
bile-duct infiltration by LCH cells and the indirect effects of an
accompanying macrophage activation syndrome leading to
hypoalbuminaemia and hepatomegaly.37
TREATMENT
Children with SS or MSRO2 disease do not die from LCH. In
these children, it does not behave as a malignancy, and the goal
of treatment is to preserve normal activity and prevent long-
term sequelae.
Single system
Treatment of isolated skin disease depends on the sites and extent
of involvement, which dictatewhether local therapymay be tried.
Sometimes minimal therapy with topical emollients may be all
that is needed. In more severe cases, topical mustine is very
effective and can safely be used in extensive and severe skin
disease.38 There are anecdotal reports of the effectiveness of other
topical agents including steroids, ciclosporin and tacrolimus. Oral
steroids alone are generally disappointing in this situation, and
additional intravenous vinblastine may be necessary if topical
therapy fails or is impractical.
A single bony lesion may heal spontaneously after biopsy or
respond to recurettage and injection of methylprednisolone
acetate. In some children, indometacin is very effective in
promoting regression of disease.39 Bony lesions are generally
exquisitely sensitive to oral prednisolone, but tend to recur on
withdrawal of treatment. This can result in a ‘‘reactivation’’
pattern which may lead to prolonged use of high-dose steroids,
especially in MF disease. There are several other reasons why
chronic reactivation is undesirable. Each episode of reactivation
may cause short-term functional problems and in the long term
contribute to permanent deformity in a facial or long bone.
Alternatively, the lesion may be in a critical anatomical site such
as the odontoid peg (fig 1) where severe consequences may
occur if rapid and complete healing is not ensured. In these
situations, it is better to commit early to treatment with
vinblastine and prednisolone, and continue with relatively low-
dose maintenance for up to 12 months.
A lesion in a base of skull or facial bone with significant
intracranial extension or proptosis is designated ‘‘special site’’
disease. Although there may be only a single lesion amenable to
local therapy, it has been advocated that if special site lesions
are not adequately treated with prolonged systemic therapy, the
chances of developing DI are increased.40 Pamidronate has been
proposed for refractory cases and appears to be particularly
helpful when pain is an issue.41
Multisystem
From its foundation in 1985, the Histiocyte Society (HS) has
been responsible for clarifying the diagnostic and staging criteria
Figure 2 Neonatal cutaneous Langerhans cell histiocytosis showing
vesicles with surrounding inflammatory weals.
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for LCH and developing a common language for treatment
evaluation. Three randomised therapeutic trials for MS disease
have been consecutively administered by the HS, initially using
data from Italian and German, Austrian and Dutch trials
opened during the 1980s.42 43
LCH I (1991–5) confirmed MSRO+ disease and a poor response
to the first 6 weeks of treatment were associated with a bad
prognosis. Therapy randomisation failed to show any advantage
of etoposide over vinblastine.8 Subsequently, LCH II (1996–
2000) did not demonstrate any benefit of combining etoposide
and vinblastine compared with vinblastine alone. The prog-
nostic significance of a poor early response in MSRO+ patients
was confirmed, and it established that age ,2 years was not an
independent predictor of poor outcome.44 Although not reported
at the time, a recently published historical comparison of LCH I
and LCH II has suggested that children who received both drugs
may have fared better.45 LCH III (2001–8), investigated adding
methotrexate to vinblastine for MSRO+ disease, and whether
6 months is as efficacious as 12 months’ therapy in terms of
preventing reactivations in MSRO2 children. The study is now
closed, and a final analysis is under way. It will be interesting to
see if this trial shows results similar to the DAL-HX study with
lower reactivation rates and incidence of diabetes insipidus in
those treated for longer periods.43
Refractory disease
Although the majority of patients with MS RO+ve disease respond
to the therapy as above, some may progress quite rapidly and
require a change to more aggressive treatment. Close monitor-
ing during the first few weeks of therapy helps to identify these
poor responders early. To salvage these patients who progress
on protocol and have a potential mortality of 66%, strategies
have been designed using high-dose AML type therapy with a
pilot study showing good results with or without allogeneic
stem cell transplantation.30 This therapy has been further
developed via international HS protocols LCH-S-98 and LCH-
S-2005, but unfortunately, owing to the extremely small
number of eligible children, and the difficulty in obtaining
regulatory approval for therapeutic studies in orphan diseases,
patient accrual has been disappointing. A sustained effort needs
to be made by centres to open such studies and recruit more
patients. More recently, low-intensity conditioning transplants
have been successfully performed, an important advance in the
treatment of children who are often desperately unwell.46
PERMANENT CONSEQUENCES
Permanent consequences resulting from destruction and scar-
ring of tissue are common in LCH. Damage may have occurred
by the time LCH is diagnosed or may not manifest until years
later. Owing to wide differences in ascertainment methodology
and patient populations studied, there is considerable variation
in the apparent prevalence of sequelae, but residual abnormal-
ities have been reported in 20–70% of survivors.12 As LCH can
result in permanent disability and significantly affect survivors’
health-related quality of life, it is important to develop uniform
criteria to define late effects and facilitate selection of patients
who need specific, standardised investigation.47
Skeletal
The skeleton is the most common site of involvement of LCH,
and sequelae have been reported in 3–42%.12 As children grow,
bones may remodel to an extent, but damage to a grow-
ing skeleton can cause disability. Chronic reactivations or
treatments such as radiation or surgery may result in permanent
damage. LCH of the spine can result in vertebra plana or
scoliosis. Limb deformities are relatively infrequent but can
occasionally lead to significant morbidity. Abnormalities of the
facial bones may persist, and residual asymmetrical proptosis is
common. Facial asymmetry may become more obvious as the
child grows and may require reconstructive surgery.
Orthodontic surgery may be needed for loss of teeth or
abnormal growth of the jaw.
Aural
Mastoid lesions can result in permanent damage and hearing
loss. Although conductive deafness is the most common
problem, permanent sensorineural hearing loss may result from
damage to the inner ear and bony labyrinth.48 Involvement of
the vestibular region is rare but presents with loss of balance in
addition to hearing loss. Children with ear involvement should
be followed up with regular audiometry and assessment, as
early diagnosis of hearing loss and the use of hearing aids can
significantly improve outcome.
Cutaneous
Depending on the severity and extent of involvement, scarring
can result in up to 30% of children who have had skin disease,
whether treated topically or systemically.38
Endocrine
LCH has a predilection for involving the posterior pituitary
gland with up to 40% of MS cases being affected.49 DI may
occur before or several years after the diagnosis of LCH. As
discussed earlier, involvement of the craniofacial bones,
especially the orbit and base of the skull, has been associated
with an increased risk of developing irreversible DI. Growth-
hormone deficiency is the next most common endocrine
abnormality, occurring in around 20% of MS cases, with other
hormone deficiencies such as secondary hypothyroidism,
gonadotrophin and corticotrophin deficiency occurring less
frequently.49 Pituitary irradiation, if used in patients with DI,
does not ameliorate the condition, may cause anterior pituitary
failure and should therefore be avoided. All children with DI,
short stature, poor growth or delayed puberty should have
anterior pituitary stimulation tests. Other factors which may
contribute to poor growth include bony destruction, chronic
steroid therapy and the effects of chronic disease.
Neurological
There is increasing awareness of the long-term sequelae of LCH
affecting the brain, including neuropsychological problems
(intellectual loss, memory impairment, learning deficit, poor
school performance, emotional disturbance and significant
cognitive impairment) and cerebellar degeneration in 12–
20%.12 Characteristically, this may manifest many years after
diagnosis with bilateral cerebellar signal changes on MRI. The
pathophysiology and natural history of neurological disease in
LCH remain unclear, and abnormalities may plateau or progress
resulting in severe disability. Although there is no proven
therapy, it is recommended that patients who have had MS
disease, craniofacial bone lesions or DI are carefully followed up
with neuropsychometric studies, with a low threshold for
performing cerebral MRI studies, to facilitate early supportive
intervention.
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Pulmonary
Although lung involvement has been reported to be present in
up to 50% of children with MS disease at diagnosis, permanent
lung damage is uncommon, with reports ranging between 1 and
8%.12 This is probably due to the ability of the young child’s
lungs to repair and replace damaged alveoli. Irreversible lung
damage predominantly occurs in young adult smokers, who
may develop endstage disease necessitating lung transplanta-
tion. All patients with LCH should be strongly recommended to
refrain from smoking.
Hepatic
Children requiring a liver transplant for acute sclerosing
cholangitis at diagnosis may survive without reactivation in
the graft, and those who respond to chemotherapy do not
necessarily go on to develop chronic liver disease and end-stage
biliary cirrhosis.50
CONCLUSIONS
More than half a century on from recognition of the common
pathology underlying the ‘‘Histiocytosis X syndromes,’’ we are
tantalisingly close to discovering the mechanisms responsible
for this anomalous histiocytic behaviour. Once the errant
processes are understood, targeted pharmacological and immu-
nological interventions will hopefully follow. In the mean time,
progress can only be made by continuing evaluation of known
drugs in alternative schedules in the context of international,
randomised clinical trials.
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